PREVALENCE Patient Summary
WHO IS THIS STUDY MEANT FOR?
The PREVALENCE study is looking for men with metastatic prostate cancer* to determine whether they have specific genetic changes.
WHY IS THIS CLINICAL RESEARCH STUDY BEING DONE?
The goal of the PREVALENCE study is to understand how often these specific genetic changes, also known as DNA-repair defects, are found in men with metastatic prostate cancer. Recent data suggests that tumor cells that have DNA repair defects may be more sensitive to certain drugs.
The study will involve one visit to the study clinic to collect your saliva, blood and/or tumor tissue sample that will be used to assess frequency of these DNA-repair defects. Your doctor may have a stored tumor sample which can also be used. You will not be given any medication in this study.
You may qualify for other Janssen-sponsored interventional studies depending on the specific genetic changes your cancer carries.
WHO CAN PARTICIPATE?
You may be eligible to participate in the PREVALENCE study if you:
Your study doctor will provide you with a detailed description of the study, as well as share possible risks and benefits before your participation to allow you to make an informed decision.
These samples contain biomarkers which provide detailed information about your cancer, including the genetic changes that cause DNA-repair defects. This may help doctors provide care that is more specific to your cancer.
If you want to learn more about biomarkers and to understand their role in clinical trials, please watch this video: What you should know about Biomarkers
To learn more about clinical trials, please visit: About Clinical Trials\Janssen Clinical Trial Finder
Organization: Janssen Research & Development, LLC
If you are interested in this trial, review the following:
PHEN Contact: 617-481-4020
Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.